TY - JOUR
T1 - Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency
AU - Rahimi-Ardabili, H.
AU - Gargari, B. Pourghassem
AU - Farzadi, Laya
PY - 2013/1
Y1 - 2013/1
N2 - Background: Vitamin D deficiency is prevalent among women, including patients with polycystic ovary syndrome (PCOS). Some studies have suggested that vitamin D may have a role in cardiovascular disease (CVD). There is very limited data on the vitamin D effect on CVD risk factors in women with PCOS and vitamin D deficiency. Aim: To investigate the effect of cholecalciferol on CVD risk factors in PCOS women with vitamin D deficiency. Methods: The study was a randomized, placebo-controlled, double blinded trial. Fifty PCOS women with vitamin D deficiency (vitamin D, no.=24; placebo, no.=26) aged 20-40 yr, were randomly assigned to receive 3 oral capsules of 50,000 IU vitamin D3 or a placebo (one capsule every 20 days) for two months. Serum vitamin D, PTH, lipid profile, apolipoprotein AI (APO-AI), and high sensitive C- reactive protein (hs-CRP) were measured at baseline and after treatment. Results: Vitamin D3 therapy in PCOS patients, increased serum vitamin D (7.00±2.80 to 22.9±6.14 ng/ml), decreased serum total cholesterol (196.6±32.8 to 179.1±34.1 mg/dl), triglyceride (156.8±73.0 to 130.5±56.5 mg/dl), and VLDL (31.4±14.6 to 26.1±11.3 mg/dl) levels significantly (p
AB - Background: Vitamin D deficiency is prevalent among women, including patients with polycystic ovary syndrome (PCOS). Some studies have suggested that vitamin D may have a role in cardiovascular disease (CVD). There is very limited data on the vitamin D effect on CVD risk factors in women with PCOS and vitamin D deficiency. Aim: To investigate the effect of cholecalciferol on CVD risk factors in PCOS women with vitamin D deficiency. Methods: The study was a randomized, placebo-controlled, double blinded trial. Fifty PCOS women with vitamin D deficiency (vitamin D, no.=24; placebo, no.=26) aged 20-40 yr, were randomly assigned to receive 3 oral capsules of 50,000 IU vitamin D3 or a placebo (one capsule every 20 days) for two months. Serum vitamin D, PTH, lipid profile, apolipoprotein AI (APO-AI), and high sensitive C- reactive protein (hs-CRP) were measured at baseline and after treatment. Results: Vitamin D3 therapy in PCOS patients, increased serum vitamin D (7.00±2.80 to 22.9±6.14 ng/ml), decreased serum total cholesterol (196.6±32.8 to 179.1±34.1 mg/dl), triglyceride (156.8±73.0 to 130.5±56.5 mg/dl), and VLDL (31.4±14.6 to 26.1±11.3 mg/dl) levels significantly (p
U2 - 10.3275/8303
DO - 10.3275/8303
M3 - Article
C2 - 22453059
SN - 0391-4097
VL - 36
SP - 28
EP - 32
JO - Journal of Endocrinological Investigation
JF - Journal of Endocrinological Investigation
ER -